Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Probabilistic radiographic atlas of glioblastoma phenotypes.

Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, Pope WB, Nghiemphu PL, Vinters HV, Liau LM, Mischel PS, Cloughesy TF.

AJNR Am J Neuroradiol. 2013 Mar;34(3):533-40. doi: 10.3174/ajnr.A3253. Epub 2012 Sep 20.

2.

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1349-55. doi: 10.3174/ajnr.A2950. Epub 2012 Feb 9.

3.

Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme.

Simon M, Ludwig M, Fimmers R, Mahlberg R, Müller-Erkwoh A, Köster G, Schramm J.

Neurosurgery. 2006 Nov;59(5):1078-85; discussion 1085.

PMID:
17016233
4.

O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.

Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T.

Int J Clin Oncol. 2010 Aug;15(4):352-8. doi: 10.1007/s10147-010-0065-6. Epub 2010 Mar 16.

PMID:
20232102
5.

Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China.

Yan W, Zhang W, You G, Bao Z, Wang Y, Liu Y, Kang C, You Y, Wang L, Jiang T.

PLoS One. 2012;7(1):e30339. doi: 10.1371/journal.pone.0030339. Epub 2012 Jan 23.

6.

Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.

Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, Nghiemphu PL, Ibrahim H, Naeini KM, Harris RJ, Lai A.

Neuroimage. 2012 Jan 16;59(2):908-16. doi: 10.1016/j.neuroimage.2011.09.076. Epub 2011 Oct 7.

7.

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.

Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schackert G, Krex D.

J Neurooncol. 2012 Dec;110(3):325-33. doi: 10.1007/s11060-012-0977-2. Epub 2012 Sep 27. Erratum in: J Neurooncol. 2013 Jan;111(1):95. Schrok, E [corrected to Schrock, E].

PMID:
23015095
8.

Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.

Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC.

Clin Cancer Res. 2009 Nov 1;15(21):6683-93. doi: 10.1158/1078-0432.CCR-08-2801. Epub 2009 Oct 27.

9.

Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.

Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, Jiang T.

Med Oncol. 2012 Jun;29(2):1292-6. doi: 10.1007/s12032-011-9901-4. Epub 2011 Mar 11.

PMID:
21394635
10.

Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.

Ha SY, Kang SY, Do IG, Suh YL.

J Neurooncol. 2013 May;112(3):439-48. doi: 10.1007/s11060-013-1073-y. Epub 2013 Feb 15.

PMID:
23412777
11.

Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.

Romano A, Calabria LF, Tavanti F, Minniti G, Rossi-Espagnet MC, Coppola V, Pugliese S, Guida D, Francione G, Colonnese C, Fantozzi LM, Bozzao A.

Eur Radiol. 2013 Feb;23(2):513-20. doi: 10.1007/s00330-012-2601-4. Epub 2012 Aug 10.

PMID:
22875158
12.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
13.

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.

Balańa C, Carrato C, Ramírez JL, Cardona AF, Berdiel M, Sánchez JJ, Tarón M, Hostalot C, Musulen E, Ariza A, Rosell R.

Clin Transl Oncol. 2011 Sep;13(9):677-85. doi: 10.1007/s12094-011-0714-x.

PMID:
21865140
14.

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY.

J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27.

PMID:
19636000
15.
16.

TERT promoter mutations in primary and secondary glioblastomas.

Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H.

Acta Neuropathol. 2013 Dec;126(6):931-7. doi: 10.1007/s00401-013-1163-0. Epub 2013 Aug 17.

PMID:
23955565
17.

Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.

Sunwoo L, Choi SH, Park CK, Kim JW, Yi KS, Lee WJ, Yoon TJ, Song SW, Kim JE, Kim JY, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Chang KH.

J Magn Reson Imaging. 2013 Feb;37(2):351-8. doi: 10.1002/jmri.23838. Epub 2012 Sep 28.

PMID:
23023975
18.

Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.

Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG 2nd.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8600-5.

19.

Long-term survivors of glioblastoma: clinical features and molecular analysis.

Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, Tominaga T.

Acta Neurochir (Wien). 2009 Nov;151(11):1349-58. doi: 10.1007/s00701-009-0387-1.

PMID:
19730774
20.

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A.

Acta Neuropathol. 2010 Dec;120(6):707-18. doi: 10.1007/s00401-010-0781-z. Epub 2010 Nov 19.

PMID:
21088844

Supplemental Content

Support Center